1 NCX-701 is a nitric oxide (NO)-releasing acetaminophen (APAP) derivative. 2 In the present study we demonstrated that NCX-701 is as eective as APAP in controlling body temperature in a rat model of endotoxin-induced fever. 3 Liver toxicity is a major complication of APAP overdosing. To investigate whether NCX-701 is hepatotoxic, BALB/C mice were injected with 100 ± 500 mg kg 71 APAP or NCX-701 alone or in combination (i.e. 500 mg kg 71 of both compounds). Our results demonstrated that although APAP caused a dose-dependent liver injury, NCX-701 was completely devoid of liver toxicity. At the dose of 500 mg kg 71 APAP caused an &40 fold increase of AST plasma levels and extensive centrilobular necrosis. 4 APAP and NCX-701 share the same metabolic pathway as demonstrated by the time-course of APAP-glucuronide concentrations in plasma and liver. 5 NCX-701 was safe in mice with pre-existing chronic liver disease. Indeed, while C57BL6 transgenic mice expressing the hepatitis B virus (HBV) at the age of 8 months were signi®cantly more susceptible to liver damage induced by APAP (500 mg kg Incubating mouse hepatocytes with APAP, but not with NCX-701, increased cell surface Fas expression and sensitized hepatocytes to death induced by challenge with a Fas-agonistic antibody. 8 Collectively, these observations suggest that APAP toxicity is Fas mediated and that NCX-701 spares the liver by acting at several checkpoints in the Fas pathway.
Introduction
Acetaminophen (paracetamol) (APAP) is a widely used overthe-counter analgesic and antipyretic drug. Although safe at therapeutic doses, ingestion of large dose (usually as an intentional overdose), causes massive centrilobular necrosis that may be fatal in humans and in animals (Poulin, 2000) . Although APAP overdose and deaths have been reported globally, self-poisoning seems to have been especially prevalent in those countries with unlimited availability such U.S.A. and U.K., where overdose cases are encountered at a rate of 100,000 per year (Hawton et al., 1996; Bond & Hite, 1999; Routledge et al., 1998; Schiodt et al., 1997) . Such regional variation, particularly epidemics of APAP suicide in U.K., suggests that there exists in these countries an entrenched mass awareness of APAP as a vehicle for suicide (Fagan & Wannan, 1996; Gunnell et al., 1997; Bridger et al., 1998) . Although a decline in APAP intoxication has recently been reported in the UK after the amount of APAP available at a single purchase without prescription was curtailed from a previously unlimited quantity to a maximum of 100 tablets (Poulin, 2000; Turvill et al., 2000; Prince et al., 2000) , APAP intoxication is still associated with a mortality of 11% and a transplant rate of 15% (Prince et al., 2000) . APAP hepatotoxicity is dose-dependent and rarely occurs at doses less than 10 ± 12 g or 150 mg kg 71 (Hawton et al., 1996; Bond & Hite, 1999; Routledge et al., 1998; Schiodt et al., 1997) . However, it is widely recognized that, in patients with chronic liver diseases, severe hepatotoxicity may develop from ingestion of therapeutic doses (3 ± 6 g/day) of APAP (Hawton et al., 1996; Bond & Hite, 1999; Routledge et al., that combining therapeutic doses of APAP with prolonged fasting or with other prescription and over-the-counter drugs, creates a situation that may lead to liver toxicity without exposure to excessive quantities, raising the question of whether a limitation of APAP sale to a maximum quantity of 8/gr would be eective in reducing unintentional intoxication (Poulin, 2000; Turvill et al., 2000; Prince et al., 2000) .
Nitric oxide (NO) releasing NSAIDs (NO ± NSAIDs), are a recently described class of NSAID derivatives generated by adding a nitroxybutyl moiety through an esther linkage to the parent NSAID (Elliott et al., 1995; Wallace et al., 1995; Fiorucci et al., 1999a; . These novel chemical entities not only lack the gastrointestinal damaging eect of classical NSAIDs, but the slow release of NO in a biological microenvironment can result in enhanced anti-in¯ammatory, anti-pyretic and analgesic eects in comparison with the parent molecules (Fiorucci et al., 1999a; . Although molecular mechanisms underlying these enhanced antiin¯ammatory properties are still under investigation, we have previously shown that exposure to NO ± NSAIDs results in a time-reversible S-nitrosylation/inhibition of several members of the interleukin (IL) 1-b converting enzyme (ICE) family of cysteine proteases. This family of proteases (recently renamed caspases) is involved in cytokine processing and apoptosis. Caspase S-nitrosylation by NO-releasing NSAIDs results in concentration-dependent inhibition of pro-in¯ammatory cytokines, IL-1b, IL-18 and IFNg, release and protection against apoptosis (Fiorucci et al., 1999b; . Even more intriguing, we have recently demonstrated that injecting mice with a NO ± aspirin derivative, protected them from acute liver failure induced by concanavallin A (Fiorucci et al., 1999b; . Since aspirin itself was unable to reproduce these eects it appears that the delivery of NO to the liver was responsible for the protection exerted by NO ± aspirin. Based on this background, we hypothesized that adding a NO-releasing moiety to the APAP molecule would change not only its ecacy as an analgesic and anti-pyretic drug, but also reduce its potential to cause liver damage. Indeed, in some animal models the new compound, the NO ± acetaminophen (NCX-701), (see Figure 1 for structure) exhibited antinociceptive and anti-in¯ammatory activity, and, in comparison with APAP, liver sparing properties (al-Swayeh et al., 2000; Futter et al., 2001) .
Since the pathogenesis of liver injury caused by APAP has been attributed to the generation of toxic metabolites (Dahlin et al., 1984) , one likely explanation for the lack of hepatotoxicity of NCX-701 is that the new compound generates reduced amount of toxic metabolites. However, this is unlikely since equimolar doses of the two compounds generate similar plasma concentrations of free APAP (al-Swayeh et al., 2000; Futter et al., 2001) . Interestingly, it has recently been demonstrated that APAP overdosing upregulates liver Fas expression and that injecting mice with a Fas antisense oligonucleotide protects from APAP hepatotoxicity (Zhang et al., 2000) .
The present study was designed to investigate whether the addition of a NO-releasing group to APAP confers to this compound the property of sparing the liver in normal and liver compromised mice.
Methods

Hepatotoxicity studies in healthy animals
Pathogen-free, male BALB/c were purchased from Harlan (Milan, Italy) and maintained for at least 1 week at 228C and with 55% relative humidity in a 12 h day/night rhythm with free access to food and water until the day of the experiment. All experiments were started between 0800 ± 1000 h, and were performed in agreement with the Italian legal requirements for animal care. For the dose-response studies, animals were administered 100, 300 or 500 mg kg 71 acetaminophen or NCX-701. Both drugs were dissolved in ethanol, ®nal volume 200 ml, and injected intraperitoneally (i.p.). Control animals, were injected i.p. with 200 ml ethanol. To test whether NCX-701 protected against liver toxicity caused by APAP, mice were cotreated with 500 mg kg 71 APAP plus 500 mg kg 71 NCX-701. After 24 h, surviving mice were sacri®ced and blood collected in heparinized tubes. After centrifugation, plasma was recovered and immediately frozen at 7408C. Plasma aspartate aminotransferase (AST) activity was measured by using a commercially available kit from Sigma (St. Louis, MO, U.S.A.) according to the manufacturer's instruction. For liver histopathology, the livers were removed and weighed, and a portion was ®xed in 10% buered formalin (pH 7.4). Liver samples were then processed by standard histopathological techniques, stained with haematoxylin and eosin (H&E), and examined for morphologic evaluation of liver injury as previously described (Fiorucci et al., 2000) .
Fever studies
Male Wistar rats weighing 175 ± 200 g were used. Under halothane anaesthesia, a radiotelemetry probe was inserted into the peritoneum. Using a DSI telemetry system, this permitted the continuous recording of the core temperature of each rat. The rats were left for one week before experiments were performed. Body temperature was recorded every 15 min. After recording basal body temperature for 2 h, each rat was given endotoxin (LPS) from E. coli (0111:B4, Sigma Chemical Co, St Louis, MO, U.S.A.) at a dose of 50 mg kg 71 intravenously. Two hours later, the rats were divided into groups (at least ®ve rats per group) and were given either vehicle (1% carboxymethylcellulose), acetaminophen or NCX-701 orally. Body temperature measurements were made for a further 4 h. The doses of acetaminophen tested were 25, 50 and 100 mg kg
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. NCX-701 was tested at doses equimolar to the doses of acetaminophen.
Effect of APAP and NCX-701 on liver injury in hepatitis B (HBV) transgenic mice
To ascertain whether NCX-701 is safe in animals with chronic liver disease, 8-month-old male C57BL6 transgenic mice expressing the HBV (Guidotti et al., 1995; Kakimi et al., 2000) and C57BL6 wild-type mice matched for sex and age were treated with 500 mg kg 71 APAP or NCX-701 and ALT plasma level and liver histology assessed. The HBV transgenic mice used in this study have been previously described (Guidotti et al., 1995) . These mice replicate HBV in the hepatocyte from an integrated greater-than-genomelength HBV transcriptional template. The level of HBV replication in the livers of these mice is comparable with that seen in the infected livers of patients with chronic hepatitis, and there is no evidence of cytopathology (Guidotti et al., 1995) . HBV expression in transgenic mice was assessed by determining the hepatitis Be antigen (HBeAg) in the serum (Abbott Laboratories, Abbott Park, III, U.S.A.). All HBV transgenic mice were HBeAg positive.
Hepatic glutathione concentrations
To investigate glutathione (GSH) liver concentrations, control, APAP-and NCX-701-treated mice (500 mg kg 71 i.p.) were sacri®ced at dierent time points (see Figure 2 ) after drug administration and livers removed. To determine GSH concentrations the livers were homogenized with 3% sulphosalicylic acid (1 : 10, w v 71 ) on ice, followed by centrifugation (10,0006g for 10 min at 48C). The resultant supernatant was mixed with 0.1 M sodium phosphate (pH 7.4) containing 10 mM 5,5'-dithiobis-(2-nitrobenzoic acid), 10 U ml 71 glutathione reductase, and 2 mM NADPH (all from Sigma Chemical Co, St. Louis, MO, U.S.A.), and the change in absorbance at 412 nm was quanti®ed. Reduced glutathione was used as the standard.
APAP and NCX-701 metabolism
APAP and NCX-701 metabolism was assessed by measuring the formation of APAP-glucuronide (i.e. the main APAP metabolite) (Kim & Lee, 1998) Quantitative determination APAP of APAP-glucuronide (Sigma Co., St. Louis, MO, U.S.A.) was carried out with a high pressure liquid chromatography (HPLC) method as previously published (Lin et al., 1996; Mirochnitchenko et al., 1999) . Brie¯y plasma and liver samples were spiked with 8 ug of acetanilide as internal standard, then mixed and passed through a nonconditioned C18 cartridge. After rinsing with water column samples were eluted with 1 ml of methanol. An aliquot of 20 ul was then injected onto the HPLC system (Varian Inc. Palo Alto, CA, U.S.A.). The separation of APAP and conjugated metabolites were achieved using an isocratic mobile phase consisting of water, phosphoric acid and methanol (75/25 by volume) at a¯ow rate of 1 ml min
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. The eluents were detected at 229 nm with a variable visual/UV detector (310 Varian Inc.). Data were collected and analysed using a computer software package (Varian Inc.). Identi®cation of APAP, NCX-701 and APAP-glucuronide was accomplished by comparison of their retention times with authentic standards.
Detection of liver DNA fragmentation
For detection of histone-associated DNA fragments, liver fragments (30 ± 40 mg) were treated in PBS with ®ve strokes of a homogenizer. The homogenate was centrifuged at 13,0006g for 20 min. The supernatant was further diluted 200-fold and directly used to determine DNA fragmentation by a commercially available ELISA cell death detection kit (Boehringer Mannheim Italy, Milan, Italy) according to the manufacturer's instructions, adapted for liver tissue, and designed to quantify cytosolic oligonucleosome-bound DNA (histone ELISA). Absorbance was measured at 405 nm (Fiorucci et al., 2000) .
Reverse transcriptase polymerase chain reaction (RT ± PCR)
After the mice had been sacri®ced, livers were removed and immediately snap-frozen on liquid nitrogen and stored at 7808C until used. Total RNA was isolated using TRIzol reagent (Life Technologies, Milan, Italy) as previously described (Fiorucci et al., 2000) . PCR was performed using speci®c primers (Stratagene; La Jolla, CA, U.S.A.). For mouse b-actin the sense primer was 5'-TGT GAT GGT GGG AAT GGG TCA G-3' and antisense 5'-TTT GAT GTC ACG CAC GAT TTC C-3'; for mouse IFNg the sense primer was 5'-TAC TGC CAC GGC ACA GTC ATT GAA-3' and antisense was 5'-GCA GCG ACT CCT TTT CCG CTT CCT-3'; for mouse iNOS the sense primer was 5'-CTT CAA CAC CAA GGT TGT CTG CAT-3' and antisense was 5'-ATG TCA TGA GCA AAG GCC CAG AAC-3' (Maxim Biothec Inc. San Francisco, CA, U.S.A.); for mouse Fas Ligand the sense primer was 5'-GCC ATC ACA ACC ACT CCC ACT-3' and the antisense was 5'-TGC TGT GGG CCC ATA TCT GTC-3'; for mouse Fas Antigen the sense primer was 5'-GAA GGA GTA CAT GGA CAA GA-3' and the antisense was 5'-TGA TAT GCA TCA CTC TTC CC-3'. PCR conditions were the same described previously (Fiorucci et al., 2000) . The b-actin primers were used as a control for both reverse transcription and the PCR reaction itself, and also for comparing the amount of products from samples obtained with the same primer.
Assessment of liver caspases activity
Caspase 1, 3, 8 and 9 activity was measured on liver samples (100 ± 150 mg) as previously described by assessing the proteolytic cleavage of speci®c¯uorogenic substrate: Ac-YVAD-AMC, Ac-DEVD-AMC, Ac-IEDT-AMC and Ac-LEHD-AMC (Alexis Corporation, Lusanne, Switzerland) respectively for caspase 1, 3, 8 and 9 (Fiorucci et al., 1999b; . Protein content was analysed using the BioRad assay (Bio-Rad Laboratories, Hercules, CA, U.S.A.).
Cytokine plasma levels
Plasma IL-1b, TNFa and IFNg concentrations were assayed using speci®c ELISA kits (Endogen, Woburn, MA, U.S.A.) according to the manufacturer's protocol. Absorbance was measured at 450 nm for both standards and experimental samples. Standard curves and cytokine concentrations were calculated via a Graph-Pad Prism software (San Jose, CA, U.S.A.).
Cell culture and cell Fas detection
NCTC cells (Istituto Zoopro®lattico, Brescia, Italy), a liver mouse cell line that express Fas and undergoes Fas-mediated apoptosis, was cultured in DMEM containing 10% foetal bovine serum and 10% calf serum. Cells were incubated for 24 h with 1 mM APAP or NCX-701 alone or in combination with 1 mg ml 71 of the Fas agonistic monoclonal antibody (mAb) Jo2 (Pharmingen, San Diego, CA, U.S.A.). The percentage of apoptotic cells was determined by assessing DNA fragmentation through the analysis of propidium iodide (PI) stained nuclei at¯ow cytometry (Fiorucci et al., 1999a ) using a Epics XL¯ow cytometer (Beckman-Coulter, Miami, FL, U.S.A.). Apoptosis was also assessed by examining DNA ladder. Fas mRNA expression on NCTC cells incubated (12 h) with APAP or NCX-701 (1 mM) was carried out according to the protocol previously described. NO-acetaminophen and liver toxicity S. Fiorucci et al For immunoblot analysis, 20 mg of total cell lysate were electrotransferred onto nitrocellulose ®lters (Bio-Rad Laboratories, Hercules, CA, U.S.A.). The membrane was then rinsed brie¯y with 20 mM Tris HCl-150 mM NaCl, pH 7.8 (TBS), blocked with 5% wt/vol skim milk in TBS-T (TBS ± 0.05% Tween 20, pH 7.8) for 30 min at room temperature to prevent non-speci®c binding, and then probed overnight at 48C with a 1 : 1000 dilution of hamster anti-mouse Fas polyclonal antibody (M20, Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.). Membranes were washed three times in TBS-T for 10 min each at room temperature and then incubated for 60 min with a 1 : 5000 dilution of horseradish peroxidase-conjugated goat anti-hamster secondary antibody (Santa Cruz Biotechnology). After further washes in TBS-T at room temperature the blots were developed with the enhanced chemiluminescent detection reaction (ECL TM Western blotting kit, Amersham International, U.K.) and exposed to Kodak Biomax ®lm. Images where then digitalized and densitometric analysis of Fas/actin immunoprecipitated carried out using a speci®c software (Kodak Digital Science ID Image Analysis Software).
Fas expression on hepatocyte cell surface NCTC cells were incubated with hamster anti-mouse Fas antigen monoclonal antibody, at 1 : 1000 dilution for 30 min at 48C. Cells were then incubated with a¯uorescein isothiocyanate (FITC)-conjugated second antibody, goat anti-hamster (Sigma Chemical Co, St. Louis, MO, U.S.A.), for 30 min at 48C, washed twice, and resuspended in PBS/ formaldehyde (0.5%). Control samples were stained with the second step reagent alone. Stained cells were analysed by Epics XL¯ow cytometer (Beckman-Coulter, Miami FL, U.S.A.), and cells were gated using forward versus side scatter to exclude dead cells and debris as previously described (Fiorucci et al., 2000) .
Data analysis
All values in the ®gures and text are expressed as mean+ s.e.mean of n observations. Data sets were compared with the ANOVA and Student's t-test when appropriate.
Results
NCX-701 is as effective as APAP as antipyretic drug
Injection of LPS caused a signi®cant increase in body temperature within 2 h (by *1.58C). Oral administration of APAP or NCX-701 dose-dependently reduced body temperature. With each drug, the greatest reduction of the fever was seen within about 90 min of administration, with a gradual loss of the eect thereafter ( Figure 1B,C) . The eects of APAP and NCX-701 did not dier signi®cantly from one another.
NCX-701 is not hepatotoxic
Injecting mice with APAP caused a time-and dose-dependent liver injury. Although at the dose of 100 mg kg 71 it had no eect on mice survival and AST plasma levels, a signi®cant increase in death number and AST release was observed in animals treated with 300 and 500 mg kg 71 (Figure 2A,B) . In contrast, treating mice with 100 ± 500 mg kg 71 NCX-701 caused no change in the AST plasma levels. Histopathological examination of liver specimens taken 24 h after APAP administration demonstrated extensive hepatocyte necrosis and apoptosis around the centrilobular vein, vacuolated hepatocytes and sinusoidal space congestion. A typical liver injury observed 24 h after 500 mg kg 71 APAP dosing is shown in Figure 2D . In contrast, treating animals with equivalent doses of NCX-701 did not cause any changes in liver histology ( Figure 2E ). Thus, in contrast to APAP, NCX-701 is not hepatotoxic.
By using an ELISA that speci®cally defect histoneassociated DNA fragments, DNA fragmentation, exceeding the pretreatment levels &20 folds, was observed in mice after APAP overdosing ( Figure 2F ). However, the activity of proapoptotic caspases (3, 8 and 9) was not increased at any time after APAP (data not shown). Treating mice with increasing doses of NCX-701 had no eect on the rate of DNA fragmentation ( Figure 2F ), although it reduced caspase-3, -8 and -9 activity of approximately 35% in comparison to basal values (data not shown).
NCX-701 and APAP have similar metabolism
Injecting mice with 500 mg kg 71 APAP caused a time dependent increase in AST plasma levels. Although signi®cant changes were detected as early as 4 h after drug dosing, maximal increase, exceeding more than 30 fold baseline values, was observed at 8 h and remained stable until 24 h. No changes in AST plasma values were documented in animals treated with 500 mg kg 71 NCX-701 ( Figure 3A ). In contrast with their dierent hepatoxicity, the two drugs demonstrated similarity in the kinetics of APAP metabolite generation as demonstrated by the time-course of liver and plasma concentrations of APAP-glucuronide ( Figure 3B ± D) . Nor was protection due to a dierent eect of NCX-701 on hepatic GSH, since all animal groups suered approximately 95% depletion of total liver GSH content at 1 h ( Figure 3D) . At 8 h, however, total GSH content returned to baseline and no further changes were measured in animals sacri®ced 24 h after drug dosing.
Effect of APAP and NCX-701 on cytokine generation
Treating mice with 500 mg kg 71 APAP upregulated liver cytokine mRNA expression and caused a time-dependent release of IL-1b and TNFa ( Figure 4B ± D) . In contrast, no changes in cytokine plasma levels or liver mRNA expression were found in animals treated with 500 mg kg 71 NCX-701. As shown in Figure 4A , although APAP, mg kg 
NCX-701 protects against APAP-induced toxicity
To investigate whether the protection aorded by NCX-701 was due to its NO-releasing group, we co-administered APAP (500 mg kg 71 ) alone or in combination with NCX-701 (500 mg kg 71 ). As illustrated in Figure 5A , although APAP alone caused a signi®cant liver toxicity, co-treating APAPinjected mice with NCX-701 almost completely protected against liver toxicity and lethality. Moreover, NCX-701 prevented Fas and FasL mRNA upregulation caused by APAP ( Figure 5B ) and inhibited IL-1b and TNFa release (data not shown).
NCX-701 is safe in HBV transgenic mice
Similarly to BALB/C mice, C57BL6 mice were sensitive to liver damage induced by APAP ( Figure 6A ). In comparison with wild-type, HBV transgenic mice developed a more severe liver injury when treated with APAP 500 mg kg 71 as assessed by AST plasma level and liver histology ( Figure 6D ). In sharp contrast with APAP, NCX-701, 500 mg kg
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, caused no damage in both wild-type C57BL6 mice and HBV transgenic mice ( Figure 6A,E) . Thus NCX-701 is safe in liver-compromised mice.
APAP sensitizes hepatocytes to Fas-induced toxicity
Because our results demonstrated that APAP administration increases liver Fas mRNA expression, we reasoned that by increasing cell Fas content, APAP renders hepatocytes more susceptible to apoptosis induced by FasL. To test this concept we incubated NCTC cells, a mouse hepatocyte cell line, with 1 mM APAP alone or in combination with Jo2, a Fas agonistic mAb (1 mg ml
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). Indeed, as demonstrated in Figure 7A , although the Jo2 mAb it self caused an approximately 2 fold increase in the rate of apoptosis (P50.05 versus control), pretreating the cells with APAP signi®cantly increased Jo2 toxicity ( Figure 7A and insert) . In contrast, coincubating the cells with NCX-701 did not sensitized to Jo2. In contrast to our in vivo ®nding, APAP failed to directly stimulate Fas mRNA expression and did not increase total cell Fas content as assessed by Western blot analysis ( Figure 7B ). However, APAP exposure increased Fas expression on the hepatocyte surface as measured by¯ow cytometry ( Figure 7C,D) . In contrast NCX-701 did not increase cell surface Fas expression.
To ascertain whether these eects were related to the NO moiety of NCX-701 and to test whether NCX-701 is metabolized by hepatocytes and releases NO, we measured nitrite/nitrate concentration in NCTC cell supernatants. As illustrated in Figure 8A , incubating NCTC cells with 100 mM NCX-701 or SNAP, but not APAP, resulted in a timedependent nitrite/nitrate generation. In addition, SNAP, 100 mM, reduced apoptotic cell death induced by APAP/Jo2 ( Figure 8B ) and, similarly to NCX-701, prevented APAPinduced Fas translocation ( Figure 8B,C) .
Discussion
The mechanism responsible for acute liver damage in APAP overdosage is still unclear (Adamson & Harman, 1993; Hinson et al., 1995; Liu et al., 1999; Michael et al., 1999; Mirochnitchenko et al., 1999; Salminen et al., 1998) . APAP is primarily metabolized in the liver by glucuronidation and sulfation while a small fraction (&4%) is metabolized to the reactive two-electron oxidation product, N-acetyl-p-benzoquinoneimine (NAPQI), by several P450 forms of the microsomal mixed-function oxidase system. NAPQI generated from a therapeutic dose of APAP is normally completely detoxi®ed by the reaction with reduced GSH (Adamson & Harman, 1993; Mirochnitchenko et al., 1999; Salminen et al., 1998) . It has been suggested that APAP toxicity develops when GSHmediated detoxi®cation mechanisms become insucient to eliminate increased amounts of NAPQI (Adamson & Harman, 1993; Hinson et al., 1995; Liu et al., 1999; Michael et al., 1999; Mirochnitchenko et al., 1999; Salminen et al., 1998) . However, even though NAPQI generation correlates with the extent of liver injury, there is evidence that other mechanistic events occurring intracellularly in parenchymal and non-parenchymal cells may be important. In particular, macrophage recruitment and activation has been implicated in APAP hepatotoxicity (Blazka et al., 1995; Boulares et al., 1999; Horbach et al., 1997; Lawson et al., 1999; . According to this concept, hepatocytes initially injured by APAP would release factors that attract and subsequently activate Kuper cells and other mononuclear phagocytes to the centrilobular regions. Although the nature of these mediators has not been elucidated, TNFa, IL-1b and chemokines, such as MIP, may be possible candidates (Blazka et al., 1995; Horbach et al., 1997) . Supporting this view macrophage depletion by gadolinium and TNFa or IL1b immunoneutralization attenuates the potential of APAP to injure the liver (Michael et al., 1999) .
In the present study we provide evidence that treating mice with sublethal doses of APAP not only upregulates IL-1b and TNFa mRNA expression but also increases Fas and FasL mRNA expression in the liver. It has recently been found (Zhang et al., 2000) that APAP (300 mg kg 71 ) increases liver Fas mRNA expression and centrilobular poly(ADP-ribose) polymerase 1 activity. A Fas-mediated pathway seems to be involved in the pathogenesis of liver damage in APAP intoxicated mice since an oligonucleotide antisense that selectively suppresses Fas expression signi®cantly attenuates liver injury caused by APAP (Zhang et al., 2000) . We now have provided further evidence for a role of Fas in the pathogenesis of liver injury caused by APAP: (1), sublethal doses of APAP, up to 500 mg kg
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, not only increase liver Fas mRNA but strongly induce FasL mRNA expression; (2), APAP increases cell surface Fas expression on hepatocytes; (3), exposure to APAP increases sensitivity of hepatocytes to FasL-induced death; and, (4), NCX-701 spares the liver and does not increase Fas and FasL expression. Taken together these data strongly suggest that a Fas/FasL mechanism mediates liver damage in APAP intoxicated mice.
Another ®nding of our study is that APAP not only stimulated liver Fas mRNA accumulation when injected in vivo but it also directly increased Fas expression on cultured hepatocytes. While cytokine release might, at least in part, account for Fas induction in vivo, the in vitro results suggest that APAP directly increases cell surface expression of Fas. Indeed, we have found that exposure of isolated hepatocytes to APAP increases Fas cell surface density without increasing Fas mRNA nor total cell Fas content. Because of the propensity for the death domains of death receptors to spontaneously associate and activate downstream signals in the apoptotic chain, the density of cell death receptors on the plasma membrane is tightly regulated (Faubion et al., 1999; Kondo et al., 1997; Sodeman et al., 2000) . One posttranscriptional mechanism for regulating Fas plasma mem- NO-acetaminophen and liver toxicity S. Fiorucci et albrane density is to sequester receptors within intracellular pools. The receptors can then be shuttled to the plasma membrane by appropriate stimuli in a regulated fashion (Faubion et al., 1999; Kondo et al., 1997; Sodeman et al., 2000) . Recently, it has been demonstrated that exposure of cultured hepatocytes to toxic concentrations of bile acids increases Fas shuttling from intracellular stores to cell membrane (Faubion et al., 1999; Kondo et al., 1997; Sodeman et al., 2000) . The increase was blocked by protein secretion inhibitors and microtubule disrupting agents. We have now provided evidence that APAP (similar to toxic bile acids), increases hepatocyte plasma membrane expression of Fas by causing Fas shuttling from intracellular pools to cell membrane. In the present study we also provided evidence that APAP induces FasL mRNA expression. This ®nding might help to explain the observation that APAP intoxication increases IL1b release, although no measurable increase of caspase 1/ICE activity could be detected in the liver. Caspase-1/ICE is required for pro-IL-1b cleavage and, hence, for release of mature IL-1b expression (Kondo et al., 1997) . However, IL1b secretion in APAP intoxicated mice occurs in the absence of any detectable increase of caspase 1 activity suggesting that this cytokine is regulated by a caspase-1 independent manner (Miwa et al., 1998) . A caspase-1 independent generation of IL-1b has been documented in another model of acute liver failure: the acute hepatitis caused by LPS in Propionibacterium acnes (P. Acnes)-sensitized mice (Tsutsui et al., 1999) . In this model of liver injury P. acnes-primed macrophages secrete biologically active IL-1b upon stimulation with FasL. The P. acnes priming rendered macrophages responsive to FasL stimulation by upregulating Fas expression. Thus FasL induction not only plays a role in causing hepatocyte cell death but might be involved in the in¯ammatory response that accompanies liver damage caused by APAP.
NCX-701 is a newly synthesized, NO-releasing, APAP derivative. Two recent reports (al-Swayeh et al., 2000; Futter et al., 2001) have demonstrated that compared with the parent molecule, this compound not only exhibits augmented anti/nociceptive activity in both rat and mouse but, intriguingly, it is also anti-in¯ammatory over a similar dose range. We have now provided evidence that NCX-701 is equally eective as APAP as an antipyretic but lacks the hepatotoxic activity of APAP. The lack of hepatotoxicity cannot be explained on the basis of a dierent metabolism, since NCX-701 generated APAP-glucuronide and APAPsulphate with similar kinetics as the parent drug (Figures 1  and 3 ). However, in contrast to APAP, NCX-701 failed to stimulate cytokine, IL-1b and TNFa, release, nor did it increase liver Fas and FasL mRNA expression in healthy animals, while it downregulated cytokine release and Fas/ FasL expression in animals challenged with APAP. Since APAP itself exerts opposite eects it is conceivable that these activities are due to the liver release of NO from the NOreleasing moiety of NCX-701. NO has previously been demonstrated to exert either hepatotoxic and hepatoprotective eects (Li & Billiar, 1999) . There is evidence (Gardner et al., 1997) that the hepatoxic eect of NO in APAP intoxicated mice is due to iNOS upregulation in the liver. Supporting the role of iNOS-derived NO as a mediator in the liver damage induced by APAP, pretreating animals with aminoguanidine, a relatively selective iNOS inhibitor, attenuated hepatic necrosis (Gardner et al., 1997) . In isolated hepatocytes APAP itself, however, is unable to directly increase iNOS, while IL-1b induces iNOS activity and potentiates APAP toxicity, suggesting that iNOS induction in APAP-treated animals is cytokine dependent (Kuo et al., 1997) . In contrast with these detrimental eects, we and others have previously demonstrated that NO protects hepatocytes in vivo and in vitro from Fas/TNFa/TRAILinduced apoptosis by causing a time reversible S-nitrosylation/inhibition of several members of caspase family (Fiorucci et al., 2000; Li & Billiar, 1999; Young-Myeong et al., 1997) . It is now clear that NO, exogenous and endogenous, inhibits pro-apoptotic caspases as well as those members of the caspase family, such as caspase-1, involved in secretion of pro-in¯ammatory cytokines such as IL-1b (Fiorucci et al., 1999a, b; Young-Myeong et al., 1997) . However, caspase S-nitrosylation/inhibition seems to be of minor relevance in protection exerted by NCX-701 since liver damage caused by APAP does not associate with caspase activation. By using cultured hepatocytes we have demonstrated that in contrast to APAP, NCX-701 does not increase cell surface Fas density and therefore does not sensitize hepatocytes to FasL. The ®nding that SNAP prevents Fas redistribution in APAP-treated hepatocytes raises the possibility that NO or NO derived compounds released from the NO moiety of NCX-701 mediate the inhibitory eect, raising the possibility that NO acts as an endogenous regulator of Fas tracking (Eiserich et al., 1999) .
In summary, we have provided evidence that NCX-701, a NO-releasing derivative of APAP, has the same antipyretic activity as the parent compound but is not hepatotoxic in normal and liver-compromised animals. We have also demonstrated that in contrast to APAP, NCX-701 does not upregulate liver Fas/FasL and cytokine production and that these eects are due to the NO-releasing moiety of the compound. Since APAP hepatotoxicity is a major clinical problem with a mortality of 11% and a transplant rate of 15%, the development of a liver sparing, fully active, APAP derivative should help to reduce this potentially preventable cause of death.
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